Department of Internal Medicine, Division of Hematology-Oncology, The Ohio State University Medical Center, Columbus, Ohio, USA.
Breast Cancer (Dove Med Press). 2010 May 24;2:13-23. doi: 10.2147/bctt.s5430.
Advanced breast cancer represents a therapeutic challenge for oncologists. Chemotherapy with anthracyclines and taxanes has improved survival in this setting, but resistant and refractory disease is common. Ixabepilone, an epothilone, is a recently approved chemotherapeutic agent, both as a single agent and in combination with capecitabine, with efficacy in patients with resistant advanced disease. In this review, the distinctive properties of this drug are discussed, as well as the clinical evidence of efficacy. Ongoing clinical trials are exploring the role of ixabepilone in several clinical settings: neoadjuvant, adjuvant, and novel combinations.
晚期乳腺癌是肿瘤学家面临的治疗挑战。蒽环类药物和紫杉烷类药物的化疗已改善了此类情况下的生存，但耐药和难治性疾病仍很常见。伊沙匹隆（epothilone）是一种新型紫杉烷类药物，作为单药以及与卡培他滨联合应用，在耐药的晚期疾病患者中具有疗效。本文讨论了该药物的独特性质及其临床疗效证据。正在进行的临床试验正在探索伊沙匹隆在多个临床环境中的作用：新辅助、辅助和新的联合治疗。
